Mainstreaming Reproductive Genetic Innovation
Four potential avenues for structuring a societal discourse on reproductive genetic innovation in the U.S.
Gene Therapy
-
Read more: Mainstreaming Reproductive Genetic Innovation -
Read more: Recharting the Course of Sickle Cell Disease – Who will Benefit? Recharting the Course of Sickle Cell Disease – Who will Benefit?
Ethical principles of health equity and justice must be examined as these new therapies are developed and progress to first-in-human clinical trials.
-
Read more: The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table
Jack Hogan can now ride his bike home at dusk after an afternoon of playing with his friends. Is that childhood rite-of-passage worth $850,000?
-
Read more: What’s in a name? Why metaphors matter for genetics research What’s in a name? Why metaphors matter for genetics research
By Mildred K. Cho, PhD In 2017, the US FDA approved a gene therapy for the first time. However, it’s important to remember that the term “gene therapy” has been an optimistic misnomer for nearly 30 years, since the first clinical trial of a gene-based intervention was initiated in 1990. Although the FDA has now…
-
Read more: Sloppy Thinking about Genetic Therapy Sloppy Thinking about Genetic Therapy
By David Orentlicher[Cross-posted at Health Law Profs blog] As NPR reported this morning, researchers in England may soon use genetic therapy to treat diseases that result from defects in mitochondrial DNA. Mitochondria create energy for cells, and they have their own genes, distinct from the genes that help determine our looks, behavior, and other traits….